Lupin launches Bumetanide Injection USP in US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Modernization and supply chain diversity drive new growth
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated